Preliminary studies in our laboratory suggest that in vivo chronic treatment of 3×Tg-AD mice and their wild-type counterpart with the ALIAmide palmitoylethanolamide (PEA) is able to reduce the upregulated expression of hippocampal AQP-4 selectively in AD-like mice. Here, AQP4 is linked to Alzheimer disease.